🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against superbug strains of the infection, according to scientists.

An International Challenge

Gonorrhoea infections are on the rise globally, with figures suggesting over 82 million instances annually. Particularly high rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Scientists anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This milestone signifies a major breakthrough in the therapy of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Results and Global Access

Based on data published in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which uses an injection and a pill. The research involved nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to license and sell the drug in a wide range of developing nations.

Clinicians directly involved have shared positive views. Access to a easy-to-administer therapy such as this is described as a "revolutionary step" for public health efforts. This is deemed crucial to lessen the impact of the infection for patients and to prevent the spread of untreatable gonorrhoea worldwide.